Investors who take an interest in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) should definitely note that the Independent Chair of the Board, Richard Douglas, recently paid US$0.64 per share to buy US$129k worth of the stock. We reckon that's a good sign, especially since the purchase boosted their holding by 103%.
In the last twelve months, the biggest single purchase by an insider was when CEO, President & Director Todd Brady bought US$418k worth of shares at a price of US$1.67 per share. That means that an insider was happy to buy shares at above the current price of US$0.64. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.
In the last twelve months Aldeyra Therapeutics insiders were buying shares, but not selling. They paid about US$1.23 on average. This is nice to see since it implies that insiders might see value around current prices. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Check out our latest analysis for Aldeyra Therapeutics
Aldeyra Therapeutics is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. From looking at our data, insiders own US$1.4m worth of Aldeyra Therapeutics stock, about 3.6% of the company. We prefer to see high levels of insider ownership.
The recent insider purchases are heartening. And an analysis of the transactions over the last year also gives us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. While the overall levels of insider ownership are below what we'd like to see, the history of transactions imply that Aldeyra Therapeutics insiders are reasonably well aligned, and optimistic for the future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Aldeyra Therapeutics. For example, Aldeyra Therapeutics has 3 warning signs (and 1 which is a bit concerning) we think you should know about.
But note: Aldeyra Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.